|
Gene: ASB11 |
Gene summary for ASB11 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ASB11 | Gene ID | 140456 |
Gene name | ankyrin repeat and SOCS box containing 11 | |
Gene Alias | ASB11 | |
Cytomap | Xp22.2 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q7Z670 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
140456 | ASB11 | HCC1 | Human | Liver | HCC | 7.77e-09 | 4.14e-01 | 0.5336 |
140456 | ASB11 | HCC2 | Human | Liver | HCC | 1.30e-15 | 1.02e+00 | 0.5341 |
140456 | ASB11 | HCC5 | Human | Liver | HCC | 3.25e-10 | 7.16e-01 | 0.4932 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000989622 | Liver | HCC | positive regulation of catabolic process | 335/7958 | 492/18723 | 3.83e-31 | 1.87e-28 | 335 |
GO:004217622 | Liver | HCC | regulation of protein catabolic process | 267/7958 | 391/18723 | 2.45e-25 | 7.38e-23 | 267 |
GO:004573222 | Liver | HCC | positive regulation of protein catabolic process | 163/7958 | 231/18723 | 4.00e-18 | 4.69e-16 | 163 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ASB11 | SNV | Missense_Mutation | c.392G>A | p.Gly131Glu | p.G131E | Q8WXH4 | protein_coding | deleterious(0.01) | probably_damaging(0.967) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ASB11 | SNV | Missense_Mutation | novel | c.845N>C | p.Glu282Ala | p.E282A | Q8WXH4 | protein_coding | tolerated(0.09) | possibly_damaging(0.579) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
ASB11 | SNV | Missense_Mutation | rs199598614 | c.949N>A | p.Glu317Lys | p.E317K | Q8WXH4 | protein_coding | tolerated(1) | benign(0.376) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
ASB11 | SNV | Missense_Mutation | c.770N>T | p.Arg257Ile | p.R257I | Q8WXH4 | protein_coding | deleterious(0) | benign(0.068) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
ASB11 | SNV | Missense_Mutation | c.175N>G | p.Ile59Val | p.I59V | Q8WXH4 | protein_coding | tolerated(0.36) | benign(0) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
ASB11 | SNV | Missense_Mutation | rs761617786 | c.227N>A | p.Gly76Glu | p.G76E | Q8WXH4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
ASB11 | SNV | Missense_Mutation | c.302N>A | p.Ser101Tyr | p.S101Y | Q8WXH4 | protein_coding | deleterious(0) | possibly_damaging(0.837) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ASB11 | SNV | Missense_Mutation | c.52N>C | p.Phe18Leu | p.F18L | Q8WXH4 | protein_coding | tolerated_low_confidence(1) | probably_damaging(0.956) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ASB11 | SNV | Missense_Mutation | novel | c.788N>A | p.Ser263Asn | p.S263N | Q8WXH4 | protein_coding | deleterious(0.04) | benign(0.023) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
ASB11 | SNV | Missense_Mutation | rs199598614 | c.949N>A | p.Glu317Lys | p.E317K | Q8WXH4 | protein_coding | tolerated(1) | benign(0.376) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |